GABRG2 variants may be resistant to valproic acid [52], and our study found that GABRG2 is highly correlated with square_ngtdm_Busyness characteristics, and GABRG2 may also be a possible therapeutic target for breast cancer. Here, GABRG2 is linked to breast carcinoma.